Combination Study for Treatment of a Cute Nonlymphocytic Leukemia of Rubomycin Plus Aracytidine Dripping in Bone Marrow
- VernacularTitle:骨髓腔给药靶向治疗急性非淋巴细胞白血病临床研究
- Author:
Yabin SHI
;
Qunxian LU
;
Dezhi LU
- Publication Type:Journal Article
- Keywords:
Acute leukemia nonlymphocytic;
Targeted therapy;
Bone marrow-blood barrier
- From:
Journal of Medical Research
2006;0(11):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the efficacy and adverse effects of rubomycin plus aracytidine(DA) dripping in bone marrow with DA dripping in vein in the treatment of acute nonlyphocytic leukemia (ANLL). Methods 60 cases of previously untreated ANLL patients were randomly divided into two groups, group A(DA dripping in bone marrow) and group B (DA dripping in vein). the efficacy and adverse effects of both groups were compared. Results The complete remission (CR) rate was 70.0% and 33.3% in group A and group B, and the total response rate was 86.7% and 50.0%, respectively. Both were significant higher than those of group B (P0.05). Conlusions The treating outcome was better in group A than that in group B for ANLL, with higher cure remission rate and lower toxic reaction.
